Oscar W. Schalm headshot

Oscar W. Schalm 1909 - 1982

The Oscar W. Schalm Lectureship, established in 1988, honors the memory of Oscar W. Schalm, a founding faculty member of the UC Davis School of Veterinary Medicine and an eminent teacher and research scientist in the fields of bovine mastitis, diagnostic veterinary hematology and clinical pathology. The lectureship promotes a tradition of scholarship, service and commitment to veterinary medicine and recognizes the lecturer’s distinguished contributions to the profession.
Evan Keller headshot

2016 Oscar W. Schalm Lecturer

Lecture Dates

Saturday, October 8

"How to build a tumor: The roles of tumor and host subpopulations"
12:00 PM
Gladys Valley Hall, Room 1020
(1 credit CE for alumni weekend registrants)

Monday, October 10

"The biology of bone cancer"
12:10 PM
Schalm Hall, Room 170

Evan T. Keller, DVM, MPVM, PhD

Dr. Keller is a Professor of Urology and Pathology, School of Medicine, University of Michigan. He is Co-Director of the Prostate Oncology program of the University of Michigan Comprehensive Cancer Center; PI of an NCIfunded Program on the Biology of Prostate Cancer Skeletal Metastasis.

Dr. Keller obtained Doctor of Veterinary Medicine (DVM) and Master of Preventive Veterinary Medicine (MPVM) degrees from the University of California and a PhD in Developmental Biology from the University of Wisconsin, Madison. He is board certified in Oncology by the American College of Veterinary Internal Medicine.

His areas of research include (1) prostate cancer metastasis research, with a special emphasis on bone metastasis and the tumor microenvironment and (2) single cell analytic methods. He is the principal investigator on multiple NIH, DOD and pharmaceutical-funded studies, including the NIA’s first
funded aging zebrafish colony.

Dr. Keller has over 200 publications to date in areas such as aging, cytokines, bone metastasis and
prostate cancer biology. He is Editor of a book on “The Biology of Skeletal Metastases.” He sits on several
foundations, NIH and Department of Defense peer review panels and sits on several Editorial boards.
He has consulted for many companies including Lilly, Parke-Davis, Pfizer, Centocor, Immunex, Amgen,
Novartis, Merck and Eisai Pharmaceuticals.

Key research accomplishments include (1) defining importance of osteoclastic activity and targeting it in
prostate cancer leading to clinical use of RANKL inhibitor (Denosumab); (2) identification of raf kinase
inhibitor protein (RKIP) as a novel metastasis suppressor gene; (3) determining the importance of the Wnt
pathway in bone metastasis; and (4) defining interleukin-6 as a contributor to castration resistant prostate cancer.